Figure 3.

SLC7A11-AS1 Knockdown Potentiates Resistant PDAC Cell Response to Gemcitabine

(A–C) SLC7A11-AS1-knockdown and control (A) BxPC-3-Gem, (B) PANC-1, and (C) AsPC-1 cells were treated with gemcitabine (1 μM) for indicated times, and cell viability was analyzed by MTT assay (n = 3). (D and E) Colony formation assays of SLC7A11-AS1-knockdown and control cells with gemcitabine treatment (1 μM) for 2 weeks (n = 3). Representative images (D) and average number of colonies (E) were shown. (F and G) Subcutaneous xenograft analysis of SLC7A11-AS1-knockdown and control PANC-1 cells (1.5 × 10⁶) in nude mice treated with gemcitabine (50 mg/kg body weight) or PBS by intraperitoneal (i.p.) injection every 4 days (n = 4). Tumor volume (F) and weight (G) were shown. *p < 0.05, **p < 0.01, ***p < 0.001.